Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers. These therapies aim to address a broad spectrum of tumors, overcome resistance mechanisms, minimize wild-type mediated toxicities, and achieve brain penetrance for treating central nervous system diseases, including brain metastases and primary brain tumors. The company's lead candidate, silevertinib (BDTX-1535), is a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor advancing in a Phase 2 trial for frontline non-small cell lung cancer (NSCLC) patients with non-classical EGFR mutations and in trials for glioblastoma (GBM) with EGFR alterations. Black Diamond Therapeutics has also licensed BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting RAF/RAS-mutant solid tumors, to Servier for further development. Headquartered in Cambridge, Massachusetts, and founded in 2014, the company focuses on precision oncology to meet unmet needs in mutation-driven cancers.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Mark A. Velleca M.D., Ph.D.

Employees

21

Headquarters

Cambridge, MA, United States

Website

www.blackdiamondtherapeutics.com